The study of drug called pridopidine confirms its efficacy and safety in the fight against Huntington's disease, say researchers.
In patients with syndrome Huntington there is a chemical imbalance in the development of dopamine. New drug stabilizes the secretion of dopamine in areas of the brain responsible for controlling movement and coordination.
According to the study authors, this is the first drug designed to reduce the loss of patients ' ability to move their muscles by themselves. The only drug currently approved for the treatment of Huntington, tetrabenazine, which treats only involuntary movements and can cause serious side effects.
"Pridopidine showed a good result in comparison with placebo, in addition it has no serious side effects. This will allow you to use it even for those patients who are treated in places that are not centers of excellence for the treatment of Huntington's disease, " concluded the researchers.
This is the first major study to prove positive results in treating the motor symptoms of this devastating disease. And, although the connection seems to be well tolerated without significant side effects, and reduces appearance of motor symptoms of the disease ,it is unknown how long the observed improvement will continue. Moreover, pridopidine does not eliminate the root cause of Huntington's disease.
Although experts agree that new treatment options for patients with this disease are desperately needed.